Wi Ce∥ Product Information and Testing - Amended

Product Information

Product Name	iPS DF6-9-9T.B
Alias	iPS-DF6-9-9T
Lot Number	DF6-9-9T.B-MCB-01
Depositor	University of Wisconsin – Laboratory of Dr. James Thomson
Banked by	WiCell
Thaw Recommendation	Thaw 1 vial into 1 well of a 6 well plate
Culture Platform	Feeder Independent
	Medium: mTeSR1
	Matrix: Matrigel
Protocol	WiCell Feeder Independent Protocol
Passage Number	p23
	These cells were cultured for 22 passages prior to freeze. WiCell adds +1 to the passage number at freeze so that the number on the vial best represents the overall passage number of the cells at thaw.
Date Vialed	03-June-2009
Vial Label	DF6-9-9T.B P23 JY EDTA 03 JUNE 2009 SOPCC038A
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.

Testing Performed by WiCell

	resungre	riorinea by	1110011	
Test Description	Test Provider	Test Method	Test Specification	Result
Post-Thaw Viable Cell Recovery	WiCell	SOP-CH-305	≥ 15 Undifferentiated Colonies, ≤ 30% Differentiation	Pass
Identity by STR	UW Molecular Diagnostics Laboratory	PowerPlex 1.2 System by Promega	Consistent with known profile	Pass
Sterility - Direct transfer method	Apptec	30744	Negative	Pass
Mycoplasma	Bionique	M250	No contamination detected	Pass
Karyotype by G-banding	WiCell	SOP-CH-003	Normal karyotype	Pass

Amendment(s):

Reason for Amendment	Date
CoA updated to include copyright information.	See signature
CoA updated for format changes, including adding fields of thaw recommendation, vial label, protocol, and banked by.	01-JUL-2013
CoA updated for clarification of test specifications, lot number, and product description, and removed text regarding technical services and iPS cells	05-OCT-2010
CoA updated for format changes, clarification of test specifications, test method, addition of test provider, culture platform, and electronic signature, and reference to WiCell instead of the NSCB	20-AUG-2010
Original CoA	02-NOV-2009



WiCell	® Product Information	and Testing - Amended
	Date of Lot Release	Quality Assurance Approval
		12/31/2013
	02-November-2009	X AMC
		AMC Quality Assurance Signed by:





Short Tandem Repeat Analysis*

Sample Report: 5611-STR UW HLA#: 61565

Sample Date: 08/25/09

Received Date: 08/25/09

Requestor: WiCell Research Institute

Test Date: 09/04/09 File Name: 090905 Report Date: 09/14/09

Sample Name: (label on tube) 5611-STR Description: DNA Extracted by WiCell

331.6 ug/mL; 260/280 = 1.93

Locus	Repeat #	STR Genotype
D16S539	5, 8-15	Identifying information
D7S820	6-14	has been redacted to
D13S317	7-15	protect donor
D5S818	7-15	confidentiality. If more information is
CSF1PO	6-15	required, please,
TPOX	6-13	contact WiCell's
Amelogenin	NA	Technical Support.
TH01	5-11	
vWA	11, 13-21	

Comments: Based on the DNA 5611-STR dated and received on 08/25/09 from WI Cell, this sample (UW HLA# 61565) matches exactly the STR profile of the human stem cell line iPS FORESKIN comprising 15 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human iPS FORESKIN stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 5611-STR DNA sample submitted corresponds to the iPS FORESKIN stem cell line and it was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%.

9-20-09

Manager

HLA/Molecular Diagnostics Laboratory

PhD, Director

Date

HLA/Molecular Diagnostics Laboratory

File: Final STR Report

^{*} Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.

Test Facility:

This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.



Report Number 815300 Page 3 of 7

WiCell Research Institute August 27, 2009

P.O. #:

STERILITY TEST REPORT

Sample Information:

hES Cells

DF6-9-9T.B WISC #1152

Date Received:

August 04, 2009

Date in Test: **Date Completed:** August 05, 2009 August 19, 2009

Test Information:

Test Codes: 30744, 30744A

Immersion, USP / 21 CFR 610.12 Procedure #: BS210WCR.201

TEST PARAMETERS	PRODUCT			
Approximate Volume Tested	0.5 mL	0.5 mL		
Number Tested	2	2		
Type of Media	SCD	FTM		
Media Volume	400 mL	400 mL		
Incubation Period	14 Days	14 Days		
Incubation Temperature	20 °C to 25 °C	30 °C to 35 °C		
RESULTS	2 NEGATIVE	2 NEGATIVE		

Page 1 Signed

Page 1 Signed

QA Reviewer

Date

Technical Reviewer

Date

Testing conducted in accordance with current Good Manufacturing Practices.





BIONIOUE TESTING LABORATORIES, INC

APPENDIX I					
Document #:	DCF3008A				
Edition #:	06				
Effective date:	9/17/2003				
Title:	DNA FLUO	ROCHROME A	SSAY RESUI	LTS	
		DROCHROME AS		u 656	ii g
Sample ID # <u>58170</u>	<u>M-250</u>	Date Rec'd:	07/29/2009	P.O. # RP2 8	390
Indicator Cells Inoculated:	Date/Initials:	7/30/09	/_ Hs		
Fixation:	Date/Initials:	8/3/09	1_ JA	_	
Staining:	Date/Initials:	8/3/09	1 DA		
TEST/CONTROL ARTICLE:					
DF6-9-9T.B-A		-			
LOT# <u>#5611</u>					
Wicell OA					

DNA FLUOROCHROME	ASSAY RESUL	TS:			
NEGATIVE:		vith staining lir smal contamina		aclear region, v	which indicates
POSITIVE:		t amount of ext al contaminatio		ning which str	ongly suggests
INCONCLUS	IVE:				
		t amount of extr al contaminatio			with low - level
	fungal or ot		contaminant of	r viral CPE. I	with bacterial, Morphology not
COMMENTS:					
Date: 8309 Results	Read by:	Date of F	Review: 8-3-0	9 Reviewed	by: SeA





APPENDIX IV

Page 1 of 2

Document#:

DCF3013D

Edition#: Effective Date:

10 07/15/2003

Title:

M-250 FINAL REPORT SHEET

M-250 FINAL REPORT

Direct Specimen Culture Procedure 3008, 3011, 3013

TO: Wicell OA

BTL SAMPLE ID#: 58170	P.O.#:	DATE REC'D:	07/29/2009
TEST/CONTROL ARTICLE:			
DF6-9-9T.B-A			

LOT#: **#5611**

DIRECT CULTURE SET-UP (DAY 0)	DATE: <u>07/29/2009</u>
INDICATOR CELL LINE (VERO)	SEE DNA FLUOROCHROME RECORD SHEET
	DATE
THIOGLYCOLLATE BROTH	DAY 7 + 🕤 <u>08/05/2009</u>
	DAY 28 + 🕞 <u>08/26/2009</u>
BROTH-FORTIFIED COMMERCIAL	
0.5 ml SAMPLE	DAY 7 + 🗇 <u>08/05/2009</u>
6.0 mL BROTH	DAY 28 + 🗇 <u>08/26/2009</u>
BROTH-MODIFIED HAYFLICK	
0.5 mL SAMPLE	DAY 7 + \bigcirc 08/05/2009
6.0 mL BROTH	DAY 28 + 🕒 <u>08/26/2009</u>
BROTH-HEART INFUSION	
0.5 mL SAMPLE	DAY 7 + 🗇 <u>08/05/2009</u>
6.0 mL BROTH	DAY 28 + 🕒 <u>08/26/2009</u>
(See Reverse)	

Document#:

DCF3013D

Edition#:

10

Effective Date:

07/15/2003

Title:

M-250 FINAL REPORT SHEET

No detectable mycoplasmal contamination

SAMPLE ID#: 58170		AEROBIC MICROAEROPHILIC	DATE
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7 DAY 14 DAY 21	+ © + © + © + © + © + ©	08/05/2009 08/12/2009 08/19/2009
AGAR PLATES-MODIFIED HAYFLICK	DAY 7 DAY 14 DAY 21	+ © + © + © + © + ©	08/05/2009 08/12/2009 08/19/2009
AGAR PLATES-HEART INFUSION	DAY 7 DAY 14 DAY 21	+ © + © + 0 + 0 + 0 + 0	08/05/2009 08/12/2009 08/19/2009
BROTH SUBCULTURES (DAY 7)		DATE: <u>08/05/2009</u>	
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7 DAY 14 DAY 21	+ © + © + + © + © +	08/12/2009 08/19/2009 08/26/2009
	DAY 14	+ 🗇 + 👵	08/19/2009

RESULTS:

876/09 Date

Laboratory Director

Ph.D.

M-250 Procedural Summary: The objective of this test is to ascertain whether or not detectable mycoplasmas are present in an in vitro cell culture sample, be it a primary culture, hybridoma, master seed stock or cell line. This procedure combines an indirect DNA staining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the inoculation of the sample into a mycoplasma-free VERO (ATCC) indicator cell line and performing a DNA fluorochrome assay after 72-120 hours of incubation. The direct culture aspect of the test utilizes three different mycoplasmal media including both broth and agar formulations. The sample is inoculated into each of the 3 broth formulations and also onto duplicate plates (0.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to fresh agar plates is carried out after 7 days incubation. Agar plates are incubated aerobically and incroaerophillically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Issuance of the final report with signature of the Laboratory Director signifies that the required controls were performed concurrently with the test sample(s) as detailed in the referenced SOPs and that all test conditions have been found to meet the required acceptance criteria for a valid test, including the appropriate results for the positive and negative controls.



WiCell Cytogenetics Report: 001231-071709 WISC 5611

Report Date: July 22, 2009

Case Details:

Cell Line: DF6-9-9T.B (5611)

Passage #: 25

Date Completed: 7/22/2009

Cell Line Gender: male

Investigator: WiCell Stem Cell Bank

Specimen: iPSC on Matrigel
Date of Sample: 7/17/2009

Tests, Reason for: MCB Testing

Results: 46,XY


Completed by

CLSp(CG), on 7/22/2009

Reviewed and interpreted by

PhD, FACMG, on 7/22/2009

Interpretation: No abnormalities were detected at the stated band level of resolution.



Cell: S01-03

Slide: C

Slide Type: Karyotyping

Cell Results: Karyotype: 46,XY

of Cells Counted: 20

of Cells Karyotyped: 4

of Cells Analyzed: 8

Band Level: 425-550

Results Transmitted by Fax / Email / Post Sent By:____

QC Review By:

Date:____

Sent To:____

Results Recorded: _____